Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia
Identifieur interne : 001443 ( Main/Exploration ); précédent : 001442; suivant : 001444Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia
Auteurs : Manolis Markianos [Grèce] ; Marios Panas [Grèce] ; Nikos Kalfakis [Grèce] ; Dimitrios Vassilopoulos [Grèce]Source :
- Annals of Neurology [ 0364-5134 ] ; 2005-04.
Abstract
Huntington's disease (HD) is a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms and by a progressive loss among other, of dopaminergic receptors in striatum, cortex, and hypothalamus. Central dopaminergic activity has been implicated in the regulation of sex hormones. Several features of testosterone deficiency, such as reduced muscle mass, depressive mood, and cognitive impairment, are often present in HD patients, but data on their testosterone levels are lacking. We assessed plasma levels of testosterone, LH, and FSH in 42 male patients with HD, confirmed by molecular genetic analysis, and searched for differences from age‐matched healthy male subjects and for relations to CAG repeat number, age, age range, 26 to 76 (mean, 50.7 ± 12.3) years; duration of illness range, 1 to 23 (mean, 6.7 ± 6.3) years; and CAG repeat numbers from 40 to 65 (45.1 ± 3.8). Disease symptomatology was assessed using the Unified Huntington's Disease Rating Scale. Testosterone and LH levels of the patients were significantly lower compared to the levels of 44 age‐matched (mean age, 48.9 ± 13.0, range, 26–76 years) healthy men. Severity of illness was negatively related to plasma testosterone levels. Further, low testosterone levels were associated with dementia but not with depression or psychotic features. Clinical studies with selected HD patients are needed to evaluate possible beneficial effects of androgen substitution therapy on cognitive functions, depression, muscle mass and strength, general well‐being, and, eventually, neuroprotective effects. Ann Neurol 2005;57:520–525
Url:
DOI: 10.1002/ana.20428
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia</title><author><name sortKey="Markianos, Manolis" sort="Markianos, Manolis" uniqKey="Markianos M" first="Manolis" last="Markianos">Manolis Markianos</name></author><author><name sortKey="Panas, Marios" sort="Panas, Marios" uniqKey="Panas M" first="Marios" last="Panas">Marios Panas</name></author><author><name sortKey="Kalfakis, Nikos" sort="Kalfakis, Nikos" uniqKey="Kalfakis N" first="Nikos" last="Kalfakis">Nikos Kalfakis</name></author><author><name sortKey="Vassilopoulos, Dimitrios" sort="Vassilopoulos, Dimitrios" uniqKey="Vassilopoulos D" first="Dimitrios" last="Vassilopoulos">Dimitrios Vassilopoulos</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:874489750AEEFB5A99BD6356BFEE5F0801366540</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/ana.20428</idno><idno type="url">https://api.istex.fr/document/874489750AEEFB5A99BD6356BFEE5F0801366540/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003081</idno><idno type="wicri:Area/Main/Curation">002C86</idno><idno type="wicri:Area/Main/Exploration">001443</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia</title><author><name sortKey="Markianos, Manolis" sort="Markianos, Manolis" uniqKey="Markianos M" first="Manolis" last="Markianos">Manolis Markianos</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Neurology, Athens University Medical School, Eginition Hospital, Athens</wicri:regionArea><wicri:noRegion>Athens</wicri:noRegion></affiliation></author><author><name sortKey="Panas, Marios" sort="Panas, Marios" uniqKey="Panas M" first="Marios" last="Panas">Marios Panas</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Neurology, Athens University Medical School, Eginition Hospital, Athens</wicri:regionArea><wicri:noRegion>Athens</wicri:noRegion></affiliation></author><author><name sortKey="Kalfakis, Nikos" sort="Kalfakis, Nikos" uniqKey="Kalfakis N" first="Nikos" last="Kalfakis">Nikos Kalfakis</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Neurology, Athens University Medical School, Eginition Hospital, Athens</wicri:regionArea><wicri:noRegion>Athens</wicri:noRegion></affiliation></author><author><name sortKey="Vassilopoulos, Dimitrios" sort="Vassilopoulos, Dimitrios" uniqKey="Vassilopoulos D" first="Dimitrios" last="Vassilopoulos">Dimitrios Vassilopoulos</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Neurology, Athens University Medical School, Eginition Hospital, Athens</wicri:regionArea><wicri:noRegion>Athens</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-04">2005-04</date><biblScope unit="volume">57</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="520">520</biblScope><biblScope unit="page" to="525">525</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">874489750AEEFB5A99BD6356BFEE5F0801366540</idno><idno type="DOI">10.1002/ana.20428</idno><idno type="ArticleID">ANA20428</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Huntington's disease (HD) is a neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms and by a progressive loss among other, of dopaminergic receptors in striatum, cortex, and hypothalamus. Central dopaminergic activity has been implicated in the regulation of sex hormones. Several features of testosterone deficiency, such as reduced muscle mass, depressive mood, and cognitive impairment, are often present in HD patients, but data on their testosterone levels are lacking. We assessed plasma levels of testosterone, LH, and FSH in 42 male patients with HD, confirmed by molecular genetic analysis, and searched for differences from age‐matched healthy male subjects and for relations to CAG repeat number, age, age range, 26 to 76 (mean, 50.7 ± 12.3) years; duration of illness range, 1 to 23 (mean, 6.7 ± 6.3) years; and CAG repeat numbers from 40 to 65 (45.1 ± 3.8). Disease symptomatology was assessed using the Unified Huntington's Disease Rating Scale. Testosterone and LH levels of the patients were significantly lower compared to the levels of 44 age‐matched (mean age, 48.9 ± 13.0, range, 26–76 years) healthy men. Severity of illness was negatively related to plasma testosterone levels. Further, low testosterone levels were associated with dementia but not with depression or psychotic features. Clinical studies with selected HD patients are needed to evaluate possible beneficial effects of androgen substitution therapy on cognitive functions, depression, muscle mass and strength, general well‐being, and, eventually, neuroprotective effects. Ann Neurol 2005;57:520–525</div></front></TEI><affiliations><list><country><li>Grèce</li></country></list><tree><country name="Grèce"><noRegion><name sortKey="Markianos, Manolis" sort="Markianos, Manolis" uniqKey="Markianos M" first="Manolis" last="Markianos">Manolis Markianos</name></noRegion><name sortKey="Kalfakis, Nikos" sort="Kalfakis, Nikos" uniqKey="Kalfakis N" first="Nikos" last="Kalfakis">Nikos Kalfakis</name><name sortKey="Panas, Marios" sort="Panas, Marios" uniqKey="Panas M" first="Marios" last="Panas">Marios Panas</name><name sortKey="Vassilopoulos, Dimitrios" sort="Vassilopoulos, Dimitrios" uniqKey="Vassilopoulos D" first="Dimitrios" last="Vassilopoulos">Dimitrios Vassilopoulos</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001443 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001443 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:874489750AEEFB5A99BD6356BFEE5F0801366540
|texte= Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia
}}
| This area was generated with Dilib version V0.6.23. |  |